- TRADE NAME: Mayzent (Novartis)
- INDICATIONS: A sphingosine1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
- SYNONYM: Mayzent
- CLASS: Sphingosine1-phosphate receptor modulator
- HALF-LIFE: ~30 hours
- FDA APPROVAL DATE: 03/26/2019
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
CYP2C9 and CYP3A4 Inducers, CYP2C9 and CYP3A4 Inhibitors, Vaccines - PREGNANCY: There are no adequate data on the developmental risk associated with the use of MAYZENT (SIPONIMOD) in pregnant women. Based on animal data and its mechanism of action, siponimod can cause fetal harm when administered to a pregnant woman. Women of childbearing potential should use effective contraception during and for 10 days after stopping siponimod.
Please login to view the rest of this drug profile.
Page last updated 07/31/2023